Pressmeddelande -
SenzaGen AB has attracted support from LU Innovation System AB to promote commercialization
Press release
SenzaGen AB has attracted support from LU Innovation System AB to promote commercialization
2014-11-17, Lund, Sweden
SenzaGen AB announces that LU Innovation System AB (LUIS) invests in the company.
SenzaGen AB, a diagnostic company working to replace animal testing, is based on research at the Department of Immunotechnology at Lund University. The company provides in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.
LU Innovation System AB (LUIS) has since 1999 been involved in spinning out 69 companies based on research from Lund University. The portfolio has now increased by the investment in SenzaGen AB.
“We have a strong connection to Lund University and the investment by LUIS acknowledges our work and provides us with the ability to take the next important steps in our commercialization strategy,” says Anki Malmborg Hager, CEO of SenzaGen AB.
“We are very pleased of being a partner in Senzagen, which we believe has a great commercial potential. The fact that their technology can replace animal experiments doesn´t make it worse”, says Linus Wiebe, Innovation Director Lund University and CEO LU Innovation System.
The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers and other routes of exposure. Based on the demand from the market the company is now gearing up its commercial operations and prepares for the launch of further products.
About SenzaGen
SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.
SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will make in vitro testing a real option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.
SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.
For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
amh@senzagen.com
+46 768 284822
Linus Wiebe, Director of Innovation, LU Innovation Systems AB
0733- 451 240
Ämnen
- Hälsa, sjukvård, läkemedel
